Using your body's age to personalize CML treatment
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how your 'biological age' (how old your body seems) affects how well you do on targeted therapy for chronic myeloid leukemia. It aims to personalize your care by combining age and frailty information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic-phase CML within the last 3 months.
- Your CML has a specific gene change (Philadelphia chromosome) that can be measured.
- You have not yet started any CML treatment (like targeted pills) – except possibly hydroxyurea.
- You can read and understand French, and you agree to be part of the study.
- You are 18 or older and covered by French social security.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This study checks “frailty” (how strong and able you are to function) to help choose better treatment for people age 60+ with certain blood cancers like acute leukemia or MDS. It may help clinicians tailor care before major treatments like transplant or CAR T-cell therapy.
This study uses a very sensitive blood test (digital PCR) to look for specific genetic mutations (changes) in the BCR::ABL1 gene in people with CML. The goal is to understand why some treatments stop working, which can help doctors choose the next best medication for you.
This study looks at whether geriatric (age-related health) evaluations help doctors choose better treatment for newly diagnosed AML (a type of leukemia). It may help translate older adults’ needs into a clearer, safer treatment plan.
This study looks at certain immune cells called macrophages in the bone marrow of people with chronic myelomonocytic leukemia (CMML). It aims to better understand the disease, which may help improve treatments in the future.
Hear when a new Leukemia,Myeloid, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.